← Back to Clinical Trials
Recruiting NCT03894917

NCT03894917 Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03894917
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center at San Antonio
Condition Carcinoma, Hepatocellular
Study Type OBSERVATIONAL
Enrollment 84 participants
Start Date 2019-09-13
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Comprehensive Geriatric Assessment (CGA)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 84 participants in total. It began in 2019-09-13 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is an observational, prospective cohort study that will recruit a diverse sample of 84 participants with newly diagnosed with unresectable, advanced hepatocellular carcinoma (HCC) at the UT Health Cancer Center in San Antonio. This study uses geriatric assessment tools with participants 65 years and older and collects adverse events and exploratory markers of aging for all participants.

Eligibility Criteria

Inclusion Criteria: * Histologically or radiographically (CT or MRI) confirmed newly diagnosed hepatocellular carcinoma. * Age 18 years and older. * Patients with advanced, unresectable HCC as determined by the treating physician. Exclusion Criteria: * Patients with resectable HCC who are still candidates for locoregional therapy * Patients receiving prior systemic or locoregional therapy

Contact & Investigator

Central Contact

Maggie Tomasini, MPH

✉ tomasinim@uthscsa.edu

📞 210-450-0507

Principal Investigator

Sukeshi Patel Arora, MD

PRINCIPAL INVESTIGATOR

Mays Cancer Center

Frequently Asked Questions

Who can join the NCT03894917 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Carcinoma, Hepatocellular. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03894917 currently recruiting?

Yes, NCT03894917 is actively recruiting participants. Contact the research team at tomasinim@uthscsa.edu for enrollment information.

Where is the NCT03894917 trial being conducted?

This trial is being conducted at San Antonio, United States.

Who is sponsoring the NCT03894917 clinical trial?

NCT03894917 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Sukeshi Patel Arora, MD at Mays Cancer Center. The trial plans to enroll 84 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology